The critical role of T cells in glucocorticoid-induced osteoporosis

被引:15
|
作者
Song, Lin [1 ]
Cao, Lijuan [1 ]
Liu, Rui [1 ]
Ma, Hui [1 ]
Li, Yanan [1 ]
Shang, Qianwen [1 ]
Zheng, Zhiyuan [1 ]
Zhang, Liying [1 ]
Zhang, Wen [1 ]
Han, Yuyi [1 ]
Zhang, Xiaoren [2 ]
Yang, Huilin [1 ]
Wang, Ying [2 ]
Melino, Gerry [3 ]
Shao, Changshun [1 ]
Shi, Yufang [1 ,2 ,3 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, State Key Lab Radiat Med & Protect, Inst Translat Med,Med Coll, Suzhou 215123, Jiangsu, Peoples R China
[2] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Key Lab Tissue Microenvironm & Tumor,Shanghai, Shanghai 200031, Peoples R China
[3] Univ Roma Tor Vergata, Dept Expt Med, TOR, Rome, Italy
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
B-CELLS; IMMUNE-SYSTEM; BONE; OSTEOIMMUNOLOGY; APOPTOSIS; RANKL; OSTEOCLASTOGENESIS; EXPRESSION; CROSSTALK; RISK;
D O I
10.1038/s41419-020-03249-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Glucocorticoids (GC) are widely used clinically, despite the presence of significant side effects, including glucocorticoid-induced osteoporosis (GIOP). While GC are believed to act directly on osteoblasts and osteoclasts to promote osteoporosis, the detailed underlying molecular mechanism of GC-induced osteoporosis is still not fully elucidated. Here, we show that lymphocytes play a pivotal role in regulating GC-induced osteoporosis. We show that GIOP could not be induced in SCID mice that lack T cells, but it could be re-established by adoptive transfer of splenic T cells from wild-type mice. As expected, T cells in the periphery are greatly reduced by GC; instead, they accumulate in the bone marrow where they are protected from GC-induced apoptosis. These bone marrow T cells in GC-treated mice express high steady-state levels of NF-kappa B receptor activator ligand (RANKL), which promotes the formation and maturation of osteoclasts and induces osteoporosis. Taken together, these findings reveal a critical role for T cells in GIOP.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Overview of glucocorticoid-induced osteoporosis
    Paget, SA
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 1999, 5 (05) : S1 - S2
  • [42] Treatment of glucocorticoid-induced osteoporosis
    Mazziotti, Gherardo
    Giustina, Andrea
    Canalis, Ernesto
    Bilezikian, John P.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2009, 1 (01) : 27 - 34
  • [43] Advances in Glucocorticoid-Induced Osteoporosis
    Debby den Uyl
    Irene E. M. Bultink
    Willem F. Lems
    Current Rheumatology Reports, 2011, 13 : 233 - 240
  • [44] Pathophysiology of glucocorticoid-induced osteoporosis
    Schnitzer, TJ
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 1999, 5 (05) : S10 - S15
  • [45] Densitometry in glucocorticoid-induced osteoporosis
    Maricic, M
    Gluck, O
    JOURNAL OF CLINICAL DENSITOMETRY, 2004, 7 (04) : 359 - 363
  • [46] Advances in glucocorticoid-induced osteoporosis
    Angeli, A
    Dovio, A
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, : 9 - 18
  • [47] PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    REID, IR
    SCHOOLER, BA
    STEWART, AW
    JOURNAL OF BONE AND MINERAL RESEARCH, 1990, 5 (06) : 619 - 623
  • [48] Glucocorticoid-induced osteoporosis: A review
    Bouvard B.
    Legrand E.
    Audran M.
    Chappard D.
    Clinical Reviews in Bone and Mineral Metabolism, 2010, 8 (1): : 15 - 26
  • [49] Management of glucocorticoid-induced osteoporosis
    Compston, Juliet
    NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (02) : 82 - 88
  • [50] Glucocorticoid-Induced Osteoporosis and Osteonecrosis
    Weinstein, Robert S.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (03) : 595 - +